F-Prime Capital

Notabene, Inc. is a New York-based company that offers a software as a service (SaaS) platform focused on crypto compliance for the financial industry. Established in 2020, Notabene provides businesses with tools to meet emerging global regulations for cryptocurrency transactions, particularly the Travel Rule. Its platform features a unified API and a comprehensive dashboard designed to assist compliance officers in managing risks associated with both Travel Rule and non-custodial transactions. By simplifying compliance processes, Notabene enables financial companies to engage with a broader range of crypto businesses, enhancing transaction confidence and supporting growth in their operations.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.

Canoe Software Inc. provides a sophisticated software solution focused on financial document and data management. Founded in 2013 and based in New York, the company specializes in automating the extraction and organization of investment documents using artificial intelligence and machine learning technologies. This enables users to efficiently convert unstructured data from various formats, such as PDFs, into actionable insights, thereby improving operational efficiency. Canoe's platform supports a wide range of clients, including single and multi-family offices, endowments, foundations, pensions, investment consultants, and financial institutions, facilitating better management of post-investment operations, monitoring, and reporting. By streamlining the data management process, Canoe helps minimize manual data entry and enhances the accuracy of financial reporting and analysis.

Quantum Circuits, Inc. specializes in the development and manufacture of quantum computers utilizing superconducting devices. Founded in 2015 and located in New Haven, Connecticut, the company aims to innovate in the field of quantum computing by delivering full-stack systems that efficiently scale. Led by Dr. Robert Schoelkopf, a prominent figure in quantum science, Quantum Circuits employs a unique dual-rail quantum qubit design that incorporates built-in hardware error detection and conversion. This approach allows for a highly scalable error-corrected system, requiring significantly fewer physical qubits per logical qubit and providing a more efficient pathway to fault-tolerant quantum computing. By focusing on solid-state quantum bits, the company enables clients to perform error-free computations, thereby accelerating research and advancing the practical applications of quantum technology.

Doceree Inc is a healthcare marketing technology company that operates a programmatic physician engagement and advertising platform. Founded in 2019 and based in Parsippany, New Jersey, with an additional office in New Delhi, India, Doceree specializes in connecting pharmaceutical and healthcare brands with healthcare professionals (HCPs). The platform enables targeted advertising and provides data analytics to help clients effectively reach and engage with HCPs in a compliant manner. Utilizing artificial intelligence and data segmentation, Doceree identifies specific HCPs across various digital platforms, including physician networking sites, medical journals, and telemedicine platforms. This approach allows healthcare industry professionals to deliver precise and transparent messaging at scale, catering to the needs of media agencies, pharmaceutical brands, medical device companies, consumer healthcare brands, and hospitals.

Better Life Partners Inc. is a healthcare provider based in Hanover, New Hampshire, focused on supporting individuals struggling with opioid use disorder in the United States. Established in 2018, the company offers a range of services including medication-assisted treatment, counseling, peer coaching, and group sessions. Better Life Partners utilizes technology to create personalized care plans that adapt to clients' needs, ensuring effective healthcare delivery through telehealth and community-based solutions. By integrating medical and behavioral healthcare, the company aims to address the complex needs of patients, providing comprehensive support to help them recover from addiction. Better Life Partners has additional offices across various locations in New Hampshire, reflecting its commitment to serving vulnerable populations.

Simon Data, Inc. is a company that specializes in developing and distributing a performance marketing platform designed to enhance customer engagement. Founded in 2013 and based in Brooklyn, New York, Simon Data provides a customer data platform that enables marketers to create complex customer segments and deliver personalized experiences. Its solutions include data ingestion, a personalization engine, multichannel automation, advanced experimentation support, and cohort-based funnel analysis. The platform's innovative approach allows organizations to implement personalization capabilities without the necessity of extensive customized data infrastructure, making it easier for brands to provide exceptional customer experiences globally.

1upHealth, Inc. operates a health data aggregation and centralization platform that facilitates secure data transmission between health systems and consumer applications. Founded in 2017 and based in Boston, Massachusetts, the company's platform consolidates health data from various electronic medical record systems into a digital health record that users can control and share with their healthcare providers. It also enables providers to access and query up-to-date patient information from multiple connected health systems. Additionally, 1upHealth's platform allows software developers to obtain clinical data from various clinics and hospitals, enhancing the ability to monitor patient activity and automate secure data sharing. By connecting disparate data sources, 1upHealth aims to improve healthcare outcomes for patients while promoting interoperability within the healthcare ecosystem.

Zus Health is a healthcare technology company founded in 2020 in Watertown, Massachusetts, by Jonathan Bush. The company develops a healthcare data platform aimed at accelerating digital health initiatives. Its platform uniquely integrates health and non-health data, offering a comprehensive view of patients while facilitating the sharing of clinical and non-clinical information across different applications. This approach empowers healthcare professionals to create customized digital technologies and services that are more affordable and accessible, addressing the common barriers in the healthcare sector. Zus Health is focused on fostering innovation among a new generation of healthcare builders, striving to enhance the overall health experience.

Canoe Software Inc. provides a sophisticated software solution focused on financial document and data management. Founded in 2013 and based in New York, the company specializes in automating the extraction and organization of investment documents using artificial intelligence and machine learning technologies. This enables users to efficiently convert unstructured data from various formats, such as PDFs, into actionable insights, thereby improving operational efficiency. Canoe's platform supports a wide range of clients, including single and multi-family offices, endowments, foundations, pensions, investment consultants, and financial institutions, facilitating better management of post-investment operations, monitoring, and reporting. By streamlining the data management process, Canoe helps minimize manual data entry and enhances the accuracy of financial reporting and analysis.

Firefly Health, Inc. is a Massachusetts-based company that develops an artificial intelligence-driven platform to connect patients with healthcare professionals. Founded in 2016, it focuses on providing primary healthcare services that emphasize accessibility and quality. The platform allows users to navigate their health while offering care for common conditions such as back pain, stomach flu, and women's health issues. Firefly Health utilizes a virtual-first approach, enabling patients to access live video appointments with primary care physicians without membership fees. This model facilitates continuous and intelligent care, empowering patients to make informed health choices and allowing clinicians to deliver consistent and proactive support.

Vendr, Inc. is a Boston-based company that specializes in a software-as-a-service (SaaS) platform designed to streamline the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr offers a comprehensive suite of services including commercial negotiations, renewal management, and contract logistics. The platform empowers finance and procurement teams by providing access to extensive data from numerous transactions, enabling them to find suitable software, negotiate favorable prices, and manage renewals effortlessly. Vendr's commitment to simplifying SaaS procurement has positioned it as a leader in the industry, further enhanced by its recent acquisition of the SaaS management platform, Blissfully.

Proximie Inc. is a health technology company based in Bedford, Massachusetts, that specializes in a telehealth platform designed for virtual surgical assistance. Founded in 2016 by Nadine Hachach-Haram, Proximie's platform enables surgeons to remotely observe and guide complex surgical procedures using augmented reality, artificial intelligence, and machine learning. This technology allows expert surgeons to connect with their peers globally, sharing knowledge and skills in real-time, regardless of their physical location. The platform is adaptable, compatible with various devices and software used in operating rooms, and can function effectively even in low bandwidth environments. Proximie aims to enhance surgical practices by democratizing access to expert guidance and fostering collaboration among medical professionals.

Invetx, Inc. is a biotechnology company focused on developing protein-based therapeutics for animal health care and veterinary medicine. Based in Boston, Massachusetts, Invetx's team comprises veterinary scientists and clinicians dedicated to discovering and creating biotherapeutics for both pets and farm animals. The company aims to enhance health outcomes in the animal health industry by leveraging biopharma technologies, supported by a network of experts in animal and human health. Through its innovative platform, Invetx is committed to advancing a portfolio of therapies and technologies designed to improve animal care and well-being.

Doceree Inc is a healthcare marketing technology company that operates a programmatic physician engagement and advertising platform. Founded in 2019 and based in Parsippany, New Jersey, with an additional office in New Delhi, India, Doceree specializes in connecting pharmaceutical and healthcare brands with healthcare professionals (HCPs). The platform enables targeted advertising and provides data analytics to help clients effectively reach and engage with HCPs in a compliant manner. Utilizing artificial intelligence and data segmentation, Doceree identifies specific HCPs across various digital platforms, including physician networking sites, medical journals, and telemedicine platforms. This approach allows healthcare industry professionals to deliver precise and transparent messaging at scale, catering to the needs of media agencies, pharmaceutical brands, medical device companies, consumer healthcare brands, and hospitals.

RightHand Robotics, Inc. specializes in the manufacturing of robotic order-picking systems designed to enhance supply chain logistics and order fulfillment across various industries, including e-commerce, food handling, and flexible manufacturing. Founded in 2015, the company is headquartered in Cambridge, Massachusetts, with an additional office in Frankfurt, Germany. RightHand Robotics offers innovative solutions like the ReFlex SF, which features a 3D-printed palm equipped with advanced servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor that aids in gentle object handling. Their technology enables robots to automatically grasp a wide range of items from bins and cases without the need for extensive data entry or parameter tuning, making their systems cost-effective and adaptable to changing business needs.

Notabene, Inc. is a New York-based company that offers a software as a service (SaaS) platform focused on crypto compliance for the financial industry. Established in 2020, Notabene provides businesses with tools to meet emerging global regulations for cryptocurrency transactions, particularly the Travel Rule. Its platform features a unified API and a comprehensive dashboard designed to assist compliance officers in managing risks associated with both Travel Rule and non-custodial transactions. By simplifying compliance processes, Notabene enables financial companies to engage with a broader range of crypto businesses, enhancing transaction confidence and supporting growth in their operations.

Funnel is a marketing analytics and reporting software that aims to streamline data collection for online advertisers and e-commerce companies. Founded in 2014 by Fredrik Skantze and Per Made, the company provides a platform that integrates with over 400 marketing and advertising sources. This allows businesses to automatically collect and structure advertising performance data, facilitating better decision-making regarding advertising spend and business growth. Funnel enables users to feed data into various tools, including Business Intelligence platforms, Data Warehouses, and visualization tools like Google Data Studio and Google Analytics. The company serves a diverse clientele, including e-commerce businesses, media agencies, brands, B2B enterprises, mobile applications, and gaming companies. Funnel operates from its headquarters in Stockholm, with an additional office in Boston.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.

Carrot Fertility, Inc. specializes in providing comprehensive fertility benefits services to employers, supporting employees throughout their fertility healthcare journey on a global scale. The company's offerings include services such as egg freezing, in vitro fertilization, adoption, donor and gestational carrier services, as well as a premium pharmacy experience for fertility medications through Carrot Rx. Additionally, Carrot Pregnancy provides virtual access to experts and on-demand doctor-approved content, while the Carrot Card allows employees to use a flexible debit card for their fertility-related expenses. By customizing these benefits, Carrot Fertility aims to deliver financial, medical, and emotional support for individuals pursuing parenthood. Founded in 2015 and headquartered in San Francisco, California, the company also maintains offices in Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

Zus Health is a healthcare technology company founded in 2020 in Watertown, Massachusetts, by Jonathan Bush. The company develops a healthcare data platform aimed at accelerating digital health initiatives. Its platform uniquely integrates health and non-health data, offering a comprehensive view of patients while facilitating the sharing of clinical and non-clinical information across different applications. This approach empowers healthcare professionals to create customized digital technologies and services that are more affordable and accessible, addressing the common barriers in the healthcare sector. Zus Health is focused on fostering innovation among a new generation of healthcare builders, striving to enhance the overall health experience.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Proximie Inc. is a health technology company based in Bedford, Massachusetts, that specializes in a telehealth platform designed for virtual surgical assistance. Founded in 2016 by Nadine Hachach-Haram, Proximie's platform enables surgeons to remotely observe and guide complex surgical procedures using augmented reality, artificial intelligence, and machine learning. This technology allows expert surgeons to connect with their peers globally, sharing knowledge and skills in real-time, regardless of their physical location. The platform is adaptable, compatible with various devices and software used in operating rooms, and can function effectively even in low bandwidth environments. Proximie aims to enhance surgical practices by democratizing access to expert guidance and fostering collaboration among medical professionals.

1upHealth, Inc. operates a health data aggregation and centralization platform that facilitates secure data transmission between health systems and consumer applications. Founded in 2017 and based in Boston, Massachusetts, the company's platform consolidates health data from various electronic medical record systems into a digital health record that users can control and share with their healthcare providers. It also enables providers to access and query up-to-date patient information from multiple connected health systems. Additionally, 1upHealth's platform allows software developers to obtain clinical data from various clinics and hospitals, enhancing the ability to monitor patient activity and automate secure data sharing. By connecting disparate data sources, 1upHealth aims to improve healthcare outcomes for patients while promoting interoperability within the healthcare ecosystem.

Firefly Health, Inc. is a Massachusetts-based company that develops an artificial intelligence-driven platform to connect patients with healthcare professionals. Founded in 2016, it focuses on providing primary healthcare services that emphasize accessibility and quality. The platform allows users to navigate their health while offering care for common conditions such as back pain, stomach flu, and women's health issues. Firefly Health utilizes a virtual-first approach, enabling patients to access live video appointments with primary care physicians without membership fees. This model facilitates continuous and intelligent care, empowering patients to make informed health choices and allowing clinicians to deliver consistent and proactive support.

Vendr, Inc. is a Boston-based company that specializes in a software-as-a-service (SaaS) platform designed to streamline the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr offers a comprehensive suite of services including commercial negotiations, renewal management, and contract logistics. The platform empowers finance and procurement teams by providing access to extensive data from numerous transactions, enabling them to find suitable software, negotiate favorable prices, and manage renewals effortlessly. Vendr's commitment to simplifying SaaS procurement has positioned it as a leader in the industry, further enhanced by its recent acquisition of the SaaS management platform, Blissfully.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.

Carrot Fertility, Inc. specializes in providing comprehensive fertility benefits services to employers, supporting employees throughout their fertility healthcare journey on a global scale. The company's offerings include services such as egg freezing, in vitro fertilization, adoption, donor and gestational carrier services, as well as a premium pharmacy experience for fertility medications through Carrot Rx. Additionally, Carrot Pregnancy provides virtual access to experts and on-demand doctor-approved content, while the Carrot Card allows employees to use a flexible debit card for their fertility-related expenses. By customizing these benefits, Carrot Fertility aims to deliver financial, medical, and emotional support for individuals pursuing parenthood. Founded in 2015 and headquartered in San Francisco, California, the company also maintains offices in Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

RightHand Robotics, Inc. specializes in the manufacturing of robotic order-picking systems designed to enhance supply chain logistics and order fulfillment across various industries, including e-commerce, food handling, and flexible manufacturing. Founded in 2015, the company is headquartered in Cambridge, Massachusetts, with an additional office in Frankfurt, Germany. RightHand Robotics offers innovative solutions like the ReFlex SF, which features a 3D-printed palm equipped with advanced servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor that aids in gentle object handling. Their technology enables robots to automatically grasp a wide range of items from bins and cases without the need for extensive data entry or parameter tuning, making their systems cost-effective and adaptable to changing business needs.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

PatientPing, Inc. is a health technology company that has established a national care coordination network designed to connect healthcare providers with real-time notifications whenever patients receive care. The network encompasses a diverse group of healthcare personnel, including physicians, nurses, case managers, and care coordinators across various settings such as hospitals, emergency departments, and skilled nursing facilities. PatientPing offers technology solutions tailored to Accountable Care Organizations (ACOs) and other healthcare providers, facilitating improved collaboration and information sharing. One of its key tools, Spotlights, leverages real-time data to identify utilization and performance trends in patient care. Founded in 2013 and headquartered in Boston, Massachusetts, PatientPing operates as a subsidiary of SVB Leerink Holdings LLC and maintains a strategic partnership with MedAllies, Inc. By fostering connections among care teams, PatientPing aims to enhance the quality and efficiency of healthcare delivery, ultimately leading to better patient outcomes.

NFlection Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of targeted therapies for rare disorders. Based in Wayne, Pennsylvania, the company primarily addresses conditions such as neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks like keratinocytic epidermal nevi and nevus sebaceous. NFlection specializes in treatments that target the Ras/Raf/MEK/ERK signaling pathway, which is often aberrantly activated in these disorders. One of its notable developments includes a soft mitogen-activated protein kinase (MEK) formulated as a cosmetically elegant gel for topical application, allowing for localized treatment while minimizing systemic side effects typically associated with orally administered MEK inhibitors. Founded in 2014, NFlection Therapeutics aims to improve patient outcomes through innovative therapeutic solutions.

NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Established in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. NodThera's drug development portfolio includes a range of potent and selective inhibitors aimed at reducing pro-inflammatory cytokines, which are crucial contributors to chronic inflammation. The company's focus encompasses treatments for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers, ultimately enabling healthcare professionals to manage these chronic diseases more effectively.

Owkin, Inc. is an artificial intelligence company that specializes in developing software aimed at improving treatment outcomes for patients, particularly in oncology. Established in 2016, with headquarters in New York and an office in Paris, Owkin employs AI tools to enhance drug discovery and accelerate clinical trials while safeguarding patient privacy through federated learning. The company offers several products, including Owkin Lab for therapeutic data connection, Owkin Loop for validated and packaged models, and a comprehensive software stack. Owkin's portfolio includes 30 live models, with an additional 40 in development, focusing on identifying new drug candidates and elucidating the mechanisms behind treatment efficacy. Co-founded by Thomas Clozel, a clinical research doctor, and Gilles Wainrib, a machine learning expert, Owkin has raised over $255 million and achieved unicorn status due to its innovative approach in addressing unmet medical needs and optimizing the drug development process.

Rallybio is a clinical-stage biopharmaceutical company focused on developing transformative therapies for patients with severe and rare disorders. Founded in 2018 and based in New Haven, Connecticut, the company is advancing its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a serious condition that can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's portfolio includes a range of promising product candidates targeting rare diseases across various therapeutic areas, including hematology, immuno-inflammation, maternal-fetal health, and metabolic disorders. The company's efforts are supported by a team of experienced professionals with extensive expertise in biopharma research and development.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

B-One Ortho Corp. is a manufacturer of orthopedic healthcare solutions, specializing in artificial joints that facilitate joint replacement surgeries. Founded in 2015 and headquartered in Cedar Knolls, New Jersey, the company also maintains offices in Shanghai and Suzhou, China. Its notable products include the B-One total hip system, which features advanced coating technology and instrumentation, as well as the Juveno bone-conserving femoral prosthesis and primary acetabular systems. These innovations aim to enhance the effectiveness of hip and knee arthroplasty, ultimately helping patients regain their mobility and improve their quality of life.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Funnel is a marketing analytics and reporting software that aims to streamline data collection for online advertisers and e-commerce companies. Founded in 2014 by Fredrik Skantze and Per Made, the company provides a platform that integrates with over 400 marketing and advertising sources. This allows businesses to automatically collect and structure advertising performance data, facilitating better decision-making regarding advertising spend and business growth. Funnel enables users to feed data into various tools, including Business Intelligence platforms, Data Warehouses, and visualization tools like Google Data Studio and Google Analytics. The company serves a diverse clientele, including e-commerce businesses, media agencies, brands, B2B enterprises, mobile applications, and gaming companies. Funnel operates from its headquarters in Stockholm, with an additional office in Boston.

Wellframe Inc. is a Boston-based company that specializes in digital care management solutions aimed at enhancing the relationship between health plans and their members. Founded in 2011, Wellframe develops a mobile patient engagement platform that utilizes real-time member-generated data and artificial intelligence to create personalized care protocols. Its offerings include a member mobile application for daily health tracking, a care team dashboard for prioritizing patient needs, and two-way communication solutions. The company also provides various services such as implementation, operational change management, and analytics. Additionally, Wellframe's digital health advocate solutions encompass intake assessments, concierge programs, and integrated workflows to enhance care management. The company's strategic partnerships with health plans nationwide allow it to deliver impactful health management solutions that empower patients and improve care outcomes.

Vendr, Inc. is a Boston-based company that specializes in a software-as-a-service (SaaS) platform designed to streamline the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr offers a comprehensive suite of services including commercial negotiations, renewal management, and contract logistics. The platform empowers finance and procurement teams by providing access to extensive data from numerous transactions, enabling them to find suitable software, negotiate favorable prices, and manage renewals effortlessly. Vendr's commitment to simplifying SaaS procurement has positioned it as a leader in the industry, further enhanced by its recent acquisition of the SaaS management platform, Blissfully.

Firefly Health, Inc. is a Massachusetts-based company that develops an artificial intelligence-driven platform to connect patients with healthcare professionals. Founded in 2016, it focuses on providing primary healthcare services that emphasize accessibility and quality. The platform allows users to navigate their health while offering care for common conditions such as back pain, stomach flu, and women's health issues. Firefly Health utilizes a virtual-first approach, enabling patients to access live video appointments with primary care physicians without membership fees. This model facilitates continuous and intelligent care, empowering patients to make informed health choices and allowing clinicians to deliver consistent and proactive support.

Simon Data, Inc. is a company that specializes in developing and distributing a performance marketing platform designed to enhance customer engagement. Founded in 2013 and based in Brooklyn, New York, Simon Data provides a customer data platform that enables marketers to create complex customer segments and deliver personalized experiences. Its solutions include data ingestion, a personalization engine, multichannel automation, advanced experimentation support, and cohort-based funnel analysis. The platform's innovative approach allows organizations to implement personalization capabilities without the necessity of extensive customized data infrastructure, making it easier for brands to provide exceptional customer experiences globally.

Buoy Health, Inc. is a health technology company based in Boston, Massachusetts, with an additional office in New York. Founded in 2014, Buoy Health specializes in artificial intelligence-driven digital health solutions that assist individuals in managing their health and healthcare options. The company offers a personalized online healthcare chatbot, known as Buoy Assistant, which analyzes symptoms, facilitates initial triage, and provides treatment recommendations. This platform enables users to conduct real-time assessments of their symptoms while simplifying the navigation of the healthcare system. Additionally, Buoy Health provides resources for employees through its Buoy Dashboard, allowing them to research benefits, access wellness programs, and connect with in-network providers. The service is available 24/7, making self-diagnosis and healthcare navigation straightforward and accessible.

Quartet Health is a New York-based company that develops a cloud-based platform designed to enhance communication and collaboration between medical providers and behavioral health providers for patient care. Founded in 2014, Quartet's platform works with health plans and systems to deliver actionable insights and reports on behavioral health conditions, aiming to improve patient outcomes. The platform also offers tools for patient self-management and ensures that mental health care is tailored to individual preferences and clinical needs, while being integrated with the broader healthcare experience and insurance coverage.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Optimus Ride is a self-driving vehicle company located in Boston, Massachusetts, specializing in the development of technologies aimed at creating efficient, sustainable, and equitable mobility systems. As a spinoff from MIT, the company leverages over 30 years of interdisciplinary research in self-driving technologies, electric vehicles, and mobility-on-demand systems. Its team possesses extensive industrial and entrepreneurial expertise, encompassing areas such as manufacturing robots, urban design, and shared vehicle fleet management. Optimus Ride focuses on implementing self-driving technology in geofenced environments, utilizing advancements in sensor fusion, mapping, computer vision, and machine learning. This enables a wide range of transportation solutions, from commercial vessel operations to various transit options.

Owkin, Inc. is an artificial intelligence company that specializes in developing software aimed at improving treatment outcomes for patients, particularly in oncology. Established in 2016, with headquarters in New York and an office in Paris, Owkin employs AI tools to enhance drug discovery and accelerate clinical trials while safeguarding patient privacy through federated learning. The company offers several products, including Owkin Lab for therapeutic data connection, Owkin Loop for validated and packaged models, and a comprehensive software stack. Owkin's portfolio includes 30 live models, with an additional 40 in development, focusing on identifying new drug candidates and elucidating the mechanisms behind treatment efficacy. Co-founded by Thomas Clozel, a clinical research doctor, and Gilles Wainrib, a machine learning expert, Owkin has raised over $255 million and achieved unicorn status due to its innovative approach in addressing unmet medical needs and optimizing the drug development process.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of precision genetic medicines utilizing its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients suffering from serious diseases by targeting specific bases in the genome without inducing double-stranded breaks in DNA. Beam Therapeutics is actively developing therapies for a range of conditions, including sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder type 1A, as well as ocular and central nervous system disorders. The company’s diverse pipeline includes several programs such as BEAM-101, BEAM-201, BEAM-301, BEAM-302, and ESCAPE, reflecting its commitment to advancing gene correction, gene modification, gene activation, gene silencing, and multiplex editing technologies.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

Nebula Genomics is a company that focuses on human genome sequencing and health data, aiming to create a comprehensive online marketplace for genomic information. Founded in 2016 by Harvard genomics pioneer George Church and his colleagues, the company is headquartered in San Francisco, California, with additional offices in Boston, Massachusetts. Nebula Genomics utilizes blockchain technology to empower consumers by allowing them to maintain control over their genomic data and receive compensation for its use. The platform aggregates extensive genetic information, enabling researchers to analyze data for accelerated drug development and personalized medicine. The company’s DNA sequencing technology covers all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, facilitating in-depth genetic analysis and variant exploration.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

B-One Ortho Corp. is a manufacturer of orthopedic healthcare solutions, specializing in artificial joints that facilitate joint replacement surgeries. Founded in 2015 and headquartered in Cedar Knolls, New Jersey, the company also maintains offices in Shanghai and Suzhou, China. Its notable products include the B-One total hip system, which features advanced coating technology and instrumentation, as well as the Juveno bone-conserving femoral prosthesis and primary acetabular systems. These innovations aim to enhance the effectiveness of hip and knee arthroplasty, ultimately helping patients regain their mobility and improve their quality of life.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Axoni is a technology company that specializes in real-time data replication and distributed ledger software for the financial services industry. Founded in 2017, it serves major financial institutions, including banks, asset managers, hedge funds, and market infrastructure firms globally, with offices in New York and London. Axoni's platform facilitates the seamless integration of traditional financial technologies with blockchain systems, offering market information and deep analysis of trends. Its solutions enable rapid deployment of critical financial networks and automate real-time data sharing among market participants, enhancing the management of legal records, lifecycle events, and cash flow calculations.

Simon Data, Inc. is a company that specializes in developing and distributing a performance marketing platform designed to enhance customer engagement. Founded in 2013 and based in Brooklyn, New York, Simon Data provides a customer data platform that enables marketers to create complex customer segments and deliver personalized experiences. Its solutions include data ingestion, a personalization engine, multichannel automation, advanced experimentation support, and cohort-based funnel analysis. The platform's innovative approach allows organizations to implement personalization capabilities without the necessity of extensive customized data infrastructure, making it easier for brands to provide exceptional customer experiences globally.

Flywire is a payments enablement and software company headquartered in Boston, Massachusetts, that specializes in providing secure payment solutions for various industries, including education and healthcare. The company leverages its proprietary global payments network, an advanced payments platform, and industry-specific software to facilitate complex transactions for over 4,000 clients worldwide. Flywire supports a diverse range of payment methods, allowing transactions in more than 140 currencies across 240 countries and territories. Its solutions aim to streamline the process of receiving reconciled domestic and international payments, enhancing cost-effectiveness and efficiency for its clients. The majority of Flywire's revenue is generated from the Americas, reflecting its strong presence in the region.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Established in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. NodThera's drug development portfolio includes a range of potent and selective inhibitors aimed at reducing pro-inflammatory cytokines, which are crucial contributors to chronic inflammation. The company's focus encompasses treatments for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers, ultimately enabling healthcare professionals to manage these chronic diseases more effectively.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of precision genetic medicines utilizing its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients suffering from serious diseases by targeting specific bases in the genome without inducing double-stranded breaks in DNA. Beam Therapeutics is actively developing therapies for a range of conditions, including sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder type 1A, as well as ocular and central nervous system disorders. The company’s diverse pipeline includes several programs such as BEAM-101, BEAM-201, BEAM-301, BEAM-302, and ESCAPE, reflecting its commitment to advancing gene correction, gene modification, gene activation, gene silencing, and multiplex editing technologies.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Quartet Health is a New York-based company that develops a cloud-based platform designed to enhance communication and collaboration between medical providers and behavioral health providers for patient care. Founded in 2014, Quartet's platform works with health plans and systems to deliver actionable insights and reports on behavioral health conditions, aiming to improve patient outcomes. The platform also offers tools for patient self-management and ensures that mental health care is tailored to individual preferences and clinical needs, while being integrated with the broader healthcare experience and insurance coverage.

Nebula Genomics is a company that focuses on human genome sequencing and health data, aiming to create a comprehensive online marketplace for genomic information. Founded in 2016 by Harvard genomics pioneer George Church and his colleagues, the company is headquartered in San Francisco, California, with additional offices in Boston, Massachusetts. Nebula Genomics utilizes blockchain technology to empower consumers by allowing them to maintain control over their genomic data and receive compensation for its use. The platform aggregates extensive genetic information, enabling researchers to analyze data for accelerated drug development and personalized medicine. The company’s DNA sequencing technology covers all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, facilitating in-depth genetic analysis and variant exploration.

Valor Performance, Inc. is a Boston-based company that specializes in leadership and performance coaching. Established in 2017, it offers a digital platform designed to enhance the mental game and mindset of professionals, particularly managers and executives. The platform provides tailored programs, performance coaching, research-based exercises, and metrics for tracking progress. Additionally, Valor Performance emphasizes a scalable approach to professional training, ensuring a premium coaching experience through both digital resources and one-on-one interactions. The company's focus on coaching and analytics aims to help clients achieve and maintain peak performance in their professional roles.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Optimus Ride is a self-driving vehicle company located in Boston, Massachusetts, specializing in the development of technologies aimed at creating efficient, sustainable, and equitable mobility systems. As a spinoff from MIT, the company leverages over 30 years of interdisciplinary research in self-driving technologies, electric vehicles, and mobility-on-demand systems. Its team possesses extensive industrial and entrepreneurial expertise, encompassing areas such as manufacturing robots, urban design, and shared vehicle fleet management. Optimus Ride focuses on implementing self-driving technology in geofenced environments, utilizing advancements in sensor fusion, mapping, computer vision, and machine learning. This enables a wide range of transportation solutions, from commercial vessel operations to various transit options.

Valor Performance, Inc. is a Boston-based company that specializes in leadership and performance coaching. Established in 2017, it offers a digital platform designed to enhance the mental game and mindset of professionals, particularly managers and executives. The platform provides tailored programs, performance coaching, research-based exercises, and metrics for tracking progress. Additionally, Valor Performance emphasizes a scalable approach to professional training, ensuring a premium coaching experience through both digital resources and one-on-one interactions. The company's focus on coaching and analytics aims to help clients achieve and maintain peak performance in their professional roles.

Apellis Pharmaceuticals Inc., established in 2009, is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts. The company specializes in developing therapeutic compounds that inhibit the complement system, focusing on autoimmune and inflammatory diseases with high unmet needs. Its lead product candidate, pegcetacoplan, is currently in Phase III trials for treating geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, and in Phase II trials for various kidney and blood disorders. Additionally, Apellis is developing APL-9 for preventing immune system activation during adeno-associated virus administration. The company collaborates with Swedish Orphan Biovitrum AB (publ) to advance pegcetacoplan for treating multiple rare diseases.

Buoy Health, Inc. is a health technology company based in Boston, Massachusetts, with an additional office in New York. Founded in 2014, Buoy Health specializes in artificial intelligence-driven digital health solutions that assist individuals in managing their health and healthcare options. The company offers a personalized online healthcare chatbot, known as Buoy Assistant, which analyzes symptoms, facilitates initial triage, and provides treatment recommendations. This platform enables users to conduct real-time assessments of their symptoms while simplifying the navigation of the healthcare system. Additionally, Buoy Health provides resources for employees through its Buoy Dashboard, allowing them to research benefits, access wellness programs, and connect with in-network providers. The service is available 24/7, making self-diagnosis and healthcare navigation straightforward and accessible.

VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.

Wellframe Inc. is a Boston-based company that specializes in digital care management solutions aimed at enhancing the relationship between health plans and their members. Founded in 2011, Wellframe develops a mobile patient engagement platform that utilizes real-time member-generated data and artificial intelligence to create personalized care protocols. Its offerings include a member mobile application for daily health tracking, a care team dashboard for prioritizing patient needs, and two-way communication solutions. The company also provides various services such as implementation, operational change management, and analytics. Additionally, Wellframe's digital health advocate solutions encompass intake assessments, concierge programs, and integrated workflows to enhance care management. The company's strategic partnerships with health plans nationwide allow it to deliver impactful health management solutions that empower patients and improve care outcomes.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

Quovo Inc. is a New York-based company that develops a data platform focused on providing financial analytics and data management solutions for small- and mid-sized investors. The platform connects to millions of consumer financial accounts across over 14,000 institutions, allowing businesses to retrieve, organize, and analyze essential financial data. Quovo's offerings include tools for portfolio data normalization and reconciliation, as well as features that streamline client onboarding and facilitate ACH payments. Its services cater to a diverse clientele, including endowments, family offices, financial advisors, and individuals, enhancing their ability to manage investments and personalize financial services. Founded in 2009, Quovo operates as a subsidiary of Plaid Inc.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Ivenix, Inc. is a medical technology company based in North Andover, Massachusetts, that specializes in developing advanced intravenous (IV) infusion systems. Founded in 2001 and previously known as Fluidnet Corporation, Ivenix focuses on creating innovative solutions to improve infusion delivery in hospital settings. The company's flagship product is a next-generation infusion management system that employs pneumatic technology to accurately measure and control fluid flow, regardless of factors such as bag height, backpressure, patient movement, and fluid viscosity. This system not only simplifies the infusion process but also integrates with clinical information systems, enabling healthcare providers to manage patient infusion data effectively. By aiming to enhance the safety and efficiency of IV therapies, Ivenix is positioned to make a significant impact in the field of medical devices.

Axoni is a technology company that specializes in real-time data replication and distributed ledger software for the financial services industry. Founded in 2017, it serves major financial institutions, including banks, asset managers, hedge funds, and market infrastructure firms globally, with offices in New York and London. Axoni's platform facilitates the seamless integration of traditional financial technologies with blockchain systems, offering market information and deep analysis of trends. Its solutions enable rapid deployment of critical financial networks and automate real-time data sharing among market participants, enhancing the management of legal records, lifecycle events, and cash flow calculations.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Turnstone Biologics Inc. is a clinical-stage biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, the company is dedicated to advancing innovative viral immunotherapies aimed at improving cancer patient survival. Its lead product, RIVAL-01, utilizes a vaccinia virus backbone that encodes several immunomodulators, including Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine, which work together to enhance immune activity and optimize the tumor microenvironment for effective cancer treatment. Additionally, Turnstone Biologics is developing next-generation tumor-infiltrating lymphocyte (TIL) therapies by isolating and expanding the most potent and tumor-reactive T cells from patients' tumors, thereby harnessing the body's own immune system to combat solid tumors. Through these innovative approaches, Turnstone Biologics aims to deliver breakthrough cancer immunotherapies that significantly improve clinical outcomes for patients.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Codeship Inc. offers hosted continuous integration solutions that facilitate the building and deployment of Docker-based applications. Founded in 2011 and based in Boston, Massachusetts, with an additional office in Vienna, Austria, Codeship provides a platform that automates the software deployment process, significantly shortening development cycles. This enables software companies to reduce the risk of bugs and accelerate innovation by streamlining the testing and release processes. Known for its fully customizable services, Codeship’s platform operates a B2D (business to developer) portal, catering to the needs of developers and businesses seeking efficient and secure integration services. In 2013, the company changed its name from Railsonfire Limited and has been a subsidiary of CloudBees, Inc. since February 2018.

Quartet Health is a New York-based company that develops a cloud-based platform designed to enhance communication and collaboration between medical providers and behavioral health providers for patient care. Founded in 2014, Quartet's platform works with health plans and systems to deliver actionable insights and reports on behavioral health conditions, aiming to improve patient outcomes. The platform also offers tools for patient self-management and ensures that mental health care is tailored to individual preferences and clinical needs, while being integrated with the broader healthcare experience and insurance coverage.

Toast, Inc. is a Boston-based restaurant technology company that specializes in developing an all-in-one point-of-sale and restaurant management platform tailored for the food service and hospitality industries. Founded in 2011, Toast offers a cloud-based system designed specifically for restaurants, enabling functionalities such as tableside ordering, real-time reporting, online ordering, and labor management. The platform serves a diverse clientele, including restaurants, cafés, bars, and bakeries, and supports over 120,000 locations across the United States. Toast generates revenue through software subscription fees, transaction processing commissions, and additional services such as hardware installation and professional support. By facilitating payment transactions on its platform, Toast processed approximately $126 billion in gross volume in 2023, demonstrating its significant role in the restaurant technology landscape.

Codeship Inc. offers hosted continuous integration solutions that facilitate the building and deployment of Docker-based applications. Founded in 2011 and based in Boston, Massachusetts, with an additional office in Vienna, Austria, Codeship provides a platform that automates the software deployment process, significantly shortening development cycles. This enables software companies to reduce the risk of bugs and accelerate innovation by streamlining the testing and release processes. Known for its fully customizable services, Codeship’s platform operates a B2D (business to developer) portal, catering to the needs of developers and businesses seeking efficient and secure integration services. In 2013, the company changed its name from Railsonfire Limited and has been a subsidiary of CloudBees, Inc. since February 2018.

PatientPing, Inc. is a health technology company that has established a national care coordination network designed to connect healthcare providers with real-time notifications whenever patients receive care. The network encompasses a diverse group of healthcare personnel, including physicians, nurses, case managers, and care coordinators across various settings such as hospitals, emergency departments, and skilled nursing facilities. PatientPing offers technology solutions tailored to Accountable Care Organizations (ACOs) and other healthcare providers, facilitating improved collaboration and information sharing. One of its key tools, Spotlights, leverages real-time data to identify utilization and performance trends in patient care. Founded in 2013 and headquartered in Boston, Massachusetts, PatientPing operates as a subsidiary of SVB Leerink Holdings LLC and maintains a strategic partnership with MedAllies, Inc. By fostering connections among care teams, PatientPing aims to enhance the quality and efficiency of healthcare delivery, ultimately leading to better patient outcomes.

VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Ivenix, Inc. is a medical technology company based in North Andover, Massachusetts, that specializes in developing advanced intravenous (IV) infusion systems. Founded in 2001 and previously known as Fluidnet Corporation, Ivenix focuses on creating innovative solutions to improve infusion delivery in hospital settings. The company's flagship product is a next-generation infusion management system that employs pneumatic technology to accurately measure and control fluid flow, regardless of factors such as bag height, backpressure, patient movement, and fluid viscosity. This system not only simplifies the infusion process but also integrates with clinical information systems, enabling healthcare providers to manage patient infusion data effectively. By aiming to enhance the safety and efficiency of IV therapies, Ivenix is positioned to make a significant impact in the field of medical devices.

Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for women's health infections, particularly bacterial vaginosis (BV). Founded in 2012 and headquartered in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut, the company specializes in the development of its lead product, Solosec (secnidazole), a next-generation 5-nitroimidazole antibiotic designed for a convenient one-dose treatment. This drug offers enhanced pharmacokinetic properties that improve efficacy and tolerability for patients. Symbiomix is supported by prominent healthcare venture capital firms and aims to address the unmet therapeutic needs in the field of gynecologic infections. Since October 2017, it has operated as a subsidiary of Lupin Inc.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.